{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:16:17Z","timestamp":1790507777084,"version":"4.1.0"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sebaceous tumours and keratoacanthomas are uncommon neoplasms that constitute important clinical criteria for Muir-Torre syndrome (MTS) diagnosis. In MTS patients, the increased risk of developing synchronous or metachronous visceral malignancies is characterised by autosomal dominant inheritance. However, there are further conditions, other than MTS, that increase the risk of sebaceous neoplasms, e.g. iatrogenic immunosuppression. In this latter scenario, the sebaceous tumours can present microsatellite instability (MSI) and loss of mismatch repair (MMR) proteins, characteristic of hereditary syndromes, even in the absence of MMR germline mutations. In this article, we examine transplant probands in which the immunosuppressive therapies unmask the MTS cutaneous phenotypes, showing MSI and loss of MMR protein expression, as demonstrated by immunohistochemistry (IHC). Furthermore, MMR genes sequencing analysis identified the presence of germline mutations in MTS-suspected individuals, in the absence of a visceral MTS phenotype. It is well known that immunosuppression plays a central role in the development of sebaceous tumours in both MTS and in non-syndromic settings. Sebaceous skin tumours\u2019 MSI status and IHC profiles can be influenced by epigenetic or iatrogenic factors; however, they constitute valuable tools and a cost-effective approach to screen individuals who otherways should undergo MMR genes direct sequencing in the context of immunosuppression. In this complex setting, the choice of the immunosuppressive drug becomes a critical decision for the management of both MTS and sporadic transplant patients, which may benefit from the administration of immunosuppressive drugs, resulting in a low impact on skin cancerogenesis.<\/jats:p>","DOI":"10.1515\/cclm-2015-1210","type":"journal-article","created":{"date-parts":[[2016,3,26]],"date-time":"2016-03-26T08:44:48Z","timestamp":1458981888000},"page":"1725-1731","source":"Crossref","is-referenced-by-count":10,"title":["Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome"],"prefix":"10.1515","volume":"54","author":[{"given":"Giovanni","family":"Ponti","sequence":"first","affiliation":[{"name":"Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Manfredini","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Tomasi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"key":"2023033110175263915_j_cclm-2015-1210_ref_001_w2aab2b8c34b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Harden PN, Fryer AA, Reece S, Smith AG, Ramsay HM. Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant recipients. Transplant Proc 2001;33:1302\u20134.10.1016\/S0041-1345(00)02486-6","DOI":"10.1016\/S0041-1345(00)02486-6"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_002_w2aab2b8c34b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Jensen P, Hansen S, M\u00f8ller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177\u201386.10.1016\/S0190-9622(99)70185-4","DOI":"10.1016\/S0190-9622(99)70185-4"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_003_w2aab2b8c34b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Ponti G, Pellacani G, Ruini C, Percesepe A, Longo C, Mandel VD, et al. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients. Fam Cancer 2014;13:553\u201361.10.1007\/s10689-014-9733-4","DOI":"10.1007\/s10689-014-9733-4"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_004_w2aab2b8c34b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Imko-Walczuk B, Kry\u015b A, Lizakowski S, D\u0119bska-\u015alizie\u0144 A, Rutkowski B, Biernat W, et al. Sebaceous carcinoma in patients receiving long-term immunosuppresive treatment: case report and literature review. Transplant Proc 2014;46:2903\u20137.10.1016\/j.transproceed.2014.09.064","DOI":"10.1016\/j.transproceed.2014.09.064"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_005_w2aab2b8c34b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Janjua TA, Citardi MJ, Sasaki CT. Sebaceous gland carcinoma: report of a case and review of literature. Am J Otolaryngol 1997;18:51\u20134.10.1016\/S0196-0709(97)90049-1","DOI":"10.1016\/S0196-0709(97)90049-1"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_006_w2aab2b8c34b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Ponti G, Losi L, Di Gregorio C, Roncucci L, Pedroni M, Scarselli A, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005;103:1018\u201325.10.1002\/cncr.2087315662714","DOI":"10.1002\/cncr.20873"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_007_w2aab2b8c34b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg 2015;41:1\u201315.10.1097\/DSS.000000000000015225521100","DOI":"10.1097\/DSS.0000000000000152"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_008_w2aab2b8c34b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Jessup CJ, Redston M, Tilton E, Reimann JD. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome. Hum Pathol 2016;49:1\u20139.10.1016\/j.humpath.2015.10.00526826402","DOI":"10.1016\/j.humpath.2015.10.005"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_009_w2aab2b8c34b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Lynch HT, Lynch PM, Pester J, Fusaro RM. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre\u2019s syndrome. Arch Intern Med 1981;141:607\u201311.10.1001\/archinte.1981.00340050059016","DOI":"10.1001\/archinte.141.5.607"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_010_w2aab2b8c34b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Ponti G, Manfredini M, Tomasi A, Pellacani G. Muir-Torre syndrome and founder mismatch repair gene mutations: a long gone historical genetic challenge. Gene 2015; Jul 2.pii:S0378\u20131119(15)00802\u20131.10.1016\/j.gene.2015.06.07826143115","DOI":"10.1016\/j.gene.2015.06.078"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_011_w2aab2b8c34b1b7b1ab2b1c11Aa","unstructured":"Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248\u201357."},{"key":"2023033110175263915_j_cclm-2015-1210_ref_012_w2aab2b8c34b1b7b1ab2b1c12Aa","unstructured":"Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996;56:4836\u201340."},{"key":"2023033110175263915_j_cclm-2015-1210_ref_013_w2aab2b8c34b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005;6:980\u20137.10.1016\/S1470-2045(05)70465-4","DOI":"10.1016\/S1470-2045(05)70465-4"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_014_w2aab2b8c34b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Stone MS, Duncan WC, McGavran MH. Torre\u2019s syndrome: exacerbation of cutaneous manifestations with immunosuppression. J Am Acad Dermatol 1986;15:1101\u20133.10.1016\/S0190-9622(86)70273-9","DOI":"10.1016\/S0190-9622(86)70273-9"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_015_w2aab2b8c34b1b7b1ab2b1c15Aa","unstructured":"Stockl FA, Dolmetsch AM, Cod\u00e8re F, Burnier MN. Sebaceous carcinoma of the eyelid in an immunocompromised patient with Muir-Torre syndrome. Can J Ophthalmol 1995;30:324\u20136."},{"key":"2023033110175263915_j_cclm-2015-1210_ref_016_w2aab2b8c34b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Paraf F, Sasseville D, Watters AK, Narod S, Ginsburg O, Shibata H, et al. Clinicopathological relevance of the association between gastrointestinal and sebaceous neoplasms: the Muir-Torre syndrome. Hum Pathol 1995;26:422\u20137.10.1016\/0046-8177(95)90144-2","DOI":"10.1016\/0046-8177(95)90144-2"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_017_w2aab2b8c34b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 2005;23:61\u20137.10.1002\/hon.75116216037","DOI":"10.1002\/hon.751"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_018_w2aab2b8c34b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R, et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol 2003;48:401\u20138.10.1067\/mjd.2003.9712637920","DOI":"10.1067\/mjd.2003.97"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_019_w2aab2b8c34b1b7b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Levi Z, Hazazi R, Kedar-Barnes I, Hodak E, Gal E, Mor E, et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant 2007;7:476\u20139.10.1111\/j.1600-6143.2006.01648.x17229076","DOI":"10.1111\/j.1600-6143.2006.01648.x"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_020_w2aab2b8c34b1b7b1ab2b1c20Aa","unstructured":"Donati M, Paolino G, Muscardin L, Panetta C, Donati P. Resolution of benign and malignant sebaceous neoplasms, in a renal transplant patient treated with everolimus. Exp Clin Transplant 2015; Apr 28 Epub."},{"key":"2023033110175263915_j_cclm-2015-1210_ref_021_w2aab2b8c34b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV, et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 2001;116:246\u201353.10.1046\/j.1523-1747.2001.01233.x11180000","DOI":"10.1046\/j.1523-1747.2001.01233.x"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_022_w2aab2b8c34b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol 2011;65:1054\u20138.e1.10.1016\/j.jaad.2010.08.00321550136","DOI":"10.1016\/j.jaad.2010.08.003"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_023_w2aab2b8c34b1b7b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Becker JC, Houben R, Vetter CS, Br\u00f6cker EB. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006;6:7.10.1186\/1471-2407-6-7138669116405733","DOI":"10.1186\/1471-2407-6-7"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_024_w2aab2b8c34b1b7b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Seo BF, Jung HW, Choi IK, Rhie JW. Sebaceous carcinoma of the suprapubic area in a liver transplant recipient. Ann Dermatol 2014;26:395\u20138.10.5021\/ad.2014.26.3.395406965424966643","DOI":"10.5021\/ad.2014.26.3.395"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_025_w2aab2b8c34b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G, et al. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol 2006;126:2302\u20137.10.1038\/sj.jid.570047516826164","DOI":"10.1038\/sj.jid.5700475"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_026_w2aab2b8c34b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Shia J. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Semin Diagn Pathol 2015;32:352\u201361.10.1053\/j.semdp.2015.02.018501883025716099","DOI":"10.1053\/j.semdp.2015.02.018"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_027_w2aab2b8c34b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 2014;109:1159\u201379.10.1038\/ajg.2014.18625070057","DOI":"10.1038\/ajg.2014.186"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_028_w2aab2b8c34b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Nagaya M, Arai Y, Matsunari H, Honda M, Nakano K, Maehara M, et al. A new system to evaluate the influence of immunosuppressive drugs on pancreatic islets using epigenetic analysis in a 3-dimensional culture. Pancreas 2015;44:778\u201385.10.1097\/MPA.000000000000036625906448","DOI":"10.1097\/MPA.0000000000000366"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_029_w2aab2b8c34b1b7b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228\u201341.10.1067\/mjd.2002.12094211807435","DOI":"10.1067\/mjd.2002.120942"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_030_w2aab2b8c34b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Hortelano S, L\u00f3pez-Collazo E, Bosc\u00e1 L. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol 1999;126:1139\u201346.10.1038\/sj.bjp.0702422156589310205001","DOI":"10.1038\/sj.bjp.0702422"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_031_w2aab2b8c34b1b7b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Almeida S, Domingues A, Rodrigues L, Oliveira CR, Rego AC. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol Dis 2004;17:435\u201344.10.1016\/j.nbd.2004.07.00215571979","DOI":"10.1016\/j.nbd.2004.07.002"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_032_w2aab2b8c34b1b7b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Moscarella E, Argenziano G, Longo C, Cota C, Ardig\u00f2 M, Stigliano V, et al. Clinical, dermoscopic and reflectance confocal microscopy features of sebaceous neoplasms in Muir-Torre syndrome. J Eur Acad Dermatol Venereol 2013;27:699\u2013705.10.1111\/j.1468-3083.2012.04539.x22471909","DOI":"10.1111\/j.1468-3083.2012.04539.x"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_033_w2aab2b8c34b1b7b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Warschaw KE, Eble JN, Hood AF, Wolverton SE, Halling KC. The Muir-Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. J Cutan Pathol 1997;24:511\u20138.10.1111\/j.1600-0560.1997.tb01326.x9331898","DOI":"10.1111\/j.1600-0560.1997.tb01326.x"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_034_w2aab2b8c34b1b7b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Cohen PR. Muir-Torre syndrome in patients with hematologic malignancies. Am J Hematol 1992;40:64\u20135.10.1002\/ajh.28304001141566750","DOI":"10.1002\/ajh.2830400114"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_035_w2aab2b8c34b1b7b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Harwood CA, Proby CM, Cerio R. Appendageal malignancies. Cancer Treat Res 2009;146:353\u201374.10.1007\/978-0-387-78574-5_2919415216","DOI":"10.1007\/978-0-387-78574-5_29"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_036_w2aab2b8c34b1b7b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Guba M, Graeb C, Jauch K-W, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004;77:1777\u201382.10.1097\/01.TP.0000120181.89206.54","DOI":"10.1097\/01.TP.0000120181.89206.54"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_037_w2aab2b8c34b1b7b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003;76:597\u2013602.10.1097\/01.TP.0000081399.75231.3B12923450","DOI":"10.1097\/01.TP.0000081399.75231.3B"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_038_w2aab2b8c34b1b7b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Man X-Y, Yang X-H, Cai S-Q, Bu Z-Y, Wu X-J, Lu Z-F, et al. Expression and localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in human epidermal appendages: a comparison study by immunofluorescence. Clin Exp Dermatol 2009;34:396\u2013401.10.1111\/j.1365-2230.2008.03104.x19309374","DOI":"10.1111\/j.1365-2230.2008.03104.x"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_039_w2aab2b8c34b1b7b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Lee SH, Jeong D, Han Y-S, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res 2015;89:1\u20138.10.4174\/astr.2015.89.1.1448102626131438","DOI":"10.4174\/astr.2015.89.1.1"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_040_w2aab2b8c34b1b7b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669\u201376.10.1038\/nm0603-66912778165","DOI":"10.1038\/nm0603-669"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_041_w2aab2b8c34b1b7b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003;5:28\u201337.10.1038\/ncb89412510191","DOI":"10.1038\/ncb894"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_042_w2aab2b8c34b1b7b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab 2014;19:373\u20139.10.1016\/j.cmet.2014.01.001397280124508508","DOI":"10.1016\/j.cmet.2014.01.001"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_043_w2aab2b8c34b1b7b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"Ponti G, Longo C. Microsatellite instability and mismatch repair protein expression in sebaceous tumors, keratocanthoma, and basal cell carcinomas with sebaceous differentiation in Muir-Torre syndrome. J Am Acad Dermatol 2013;68:509\u201310.10.1016\/j.jaad.2012.09.05423394915","DOI":"10.1016\/j.jaad.2012.09.054"},{"key":"2023033110175263915_j_cclm-2015-1210_ref_044_w2aab2b8c34b1b7b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998;95:8698\u2013702.10.1073\/pnas.95.15.8698211399671741","DOI":"10.1073\/pnas.95.15.8698"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2016.54.issue-11\/cclm-2015-1210\/cclm-2015-1210.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1210\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1210\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:44:36Z","timestamp":1680263076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1210\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,25]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,5,19]]},"published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["10.1515\/cclm-2015-1210"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2015-1210","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,25]]}}}